Commercial strategy

Competitive intelligence and disease landscapes

Know which trials and treatments compete with your asset, and what each new result means for your plan.

What we do

We map pipeline assets by indication, mechanism, development stage and treatment setting, and connect them to current standard of care and unmet need.

When results come out, we look at the patients enrolled, the comparator and where the drug could fit in practice. Then we say whether your forecast or development plan should change. Recurring updates focus on what matters to a specific decision.

Before NextIndication, our team built epidemiology models across 12 oncology projects and patient-based forecasts for more than ten oncology assets.

How it works

Four steps, nothing hidden.

  1. 1

    Scope

    Agree the indication, the competitors and the decision the work supports.

  2. 2

    Map

    Build the asset database and the landscape from public and licensed sources.

  3. 3

    Monitor

    Collect sources on a schedule and detect what changed.

  4. 4

    Interpret

    Report the changes that matter and what they mean for you.

Questions teams ask

Before you start.

Which sources do you use?

Trial registries, publications, conference abstracts, company disclosures and any licensed research you hold.

Can monitoring be automated?

The collection and change detection can. We build a repeatable public-source workflow, and a person reviews and interprets what changed.

How often do updates arrive?

On the schedule that fits the decision, for example monthly or around major congresses and readouts.